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Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by a progressive loss of lower
motor neurons in the spinal cord. The incretin hormone, glucagon-like peptide-1 (GLP-1), facilitates insulin signaling, and
the long acting GLP-1 receptor agonist exendin-4 (Ex-4) is currently used as an anti-diabetic drug. GLP-1 receptors are
widely expressed in the brain and spinal cord, and our prior studies have shown that Ex-4 is neuroprotective in several
neurodegenerative disease rodent models, including stroke, Parkinson’s disease and Alzheimer’s disease. Here we
hypothesized that Ex-4 may provide neuroprotective activity in ALS, and hence characterized Ex-4 actions in both cell
culture (NSC-19 neuroblastoma cells) and in vivo (SOD1 G93A mutant mice) models of ALS. Ex-4 proved to be neurotrophic
in NSC-19 cells, elevating choline acetyltransferase (ChAT) activity, as well as neuroprotective, protecting cells from
hydrogen peroxide-induced oxidative stress and staurosporine-induced apoptosis. Additionally, in both wild-type SOD1 and
mutant SOD1 (G37R) stably transfected NSC-19 cell lines, Ex-4 protected against trophic factor withdrawal-induced toxicity.
To assess in vivo translation, SOD1 mutant mice were administered vehicle or Ex-4 at 6-weeks of age onwards to end-stage
disease via subcutaneous osmotic pump to provide steady-state infusion. ALS mice treated with Ex-4 showed improved
glucose tolerance and normalization of behavior, as assessed by running wheel, compared to control ALS mice.
Furthermore, Ex-4 treatment attenuated neuronal cell death in the lumbar spinal cord; immunohistochemical analysis
demonstrated the rescue of neuronal markers, such as ChAT, associated with motor neurons. Together, our results suggest
that GLP-1 receptor agonists warrant further evaluation to assess whether their neuroprotective potential is of therapeutic
relevance in ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s
disease and motor neuron disease, is an incurable neurodegener-
ative disorder of the voluntary motor system. Characterized by
selective and progressive death of motor neurons within the brain
and spinal cord, it leads to paralysis of voluntary muscles and,
eventually, death within five years of clinical onset [1,2]. Although
most cases of ALS occur sporadically with unknown etiology,
approximately 10% are inherited in an autosomal dominant
manner [3]. Of these, 20% are caused by mutations within the
gene encoding the superoxide dismutase 1 (SOD-1) protein, an
enzyme involved in the detoxification of reactive oxygen species.
Transgenic mice expressing the same SOD1 mutations as human,
in particular the G93A point mutation, exhibit similar histopath-
ological and clinical phenotypes as ALS patients [4,5], and hence
have been widely used to elucidate mechanisms inducing ALS
pathology as well as to screen for potential therapeutics [4].
Presently, however, riluzole, an anti-excitotoxic agent that reduces
the release of presynaptic glutamate, is the sole agent approved for
ALS treatment [1,2,6]. Whereas riluzole provides some survival
benefit, extending lifespan by 3–5 months, it does not significantly
modify muscle strength or functional outcome. Hence new
medications are needed to maintain the survival of motor neurons
and slow the decline in independent function for patients with this
incurable disease [1].
The endogenous incretin, glucagon-like peptide-1 (GLP-1), is a
30 amino acid hormone that stimulates glucose-dependent insulin
secretion and inhibits both glucagon secretion and gastric
emptying following food ingestion [7]. The long-acting GLP-1
receptor (GLP-1R) agonists exendin-4 (Ex-4) and liraglutide are
approved therapeutics for the treatment of type 2 diabetes mellitus
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they effectively lower blood glucose levels during hyperglycemia,
but not euglycemia, and can hence be safely given to nondiabetic
subjects [7,8].
In addition to their presence on pancreatic b-cells, GLP-1
receptors (GLP-1R) are widely distributed and present on neurons
within the brain and peripheral nervous system [7,9–11]. GLP-1
and analogues have been reported to cross the blood-brain barrier
[12,13] and act as neurotrophic factors in the brain, inducing
neurite outgrowth [14] as well as tyrosine hydroxylase expression
[15,16]. Similar to the action of Ex-4 on pancreatic b-cells, GLP-1
analogues have demonstrated anti-apoptotic actions in neuronal
cultures; thereby providing protection against oxidative stress,
hypoxia and trophic factor withdrawal [14,15,17]. Such actions
appear to effectively translate to in vivo, where GLP-1 and
analogues have reduced brain damage and improved functional
outcome in a transient middle cerebral artery occlusion stroke
model [15,18], as well as in multiple animal models of Parkinson’s
disease (PD), induced by MPTP, 6-OHDA or LPS [15,19–21].
Likewise, GLP-1 analogues have demonstrated favorable actions
in rodent models of peripheral neuropathy [22] as well as
Alzheimer’s disease (AD) [17,23]. In addition to neuroprotection,
an elevation in neuronal progenitor cells was evident within the
brain of GLP-1 agonist-treated animals [19,20,23] indicative of
the induction of neuroregenerative processes.
The brain is a highly insulin sensitive organ and T2DM is
known as a risk factor for many neurodegenerative diseases,
including AD and PD in which the repositioning of Ex-4 is already
being assessed as a new clinical treatment strategy. As glucose
intolerance and insulin resistance have been linked to ALS
[24,25], and in light of the neurotrophic and protective actions of
GLP-1R activation in diverse cellular and animal models of
neurodegeneration, we hypothesize that GLP-1 and analogues
may provide neuroprotective actions in ALS. To test this
hypothesis, we investigated the therapeutic potential of Ex-4 in
both cell culture and rodent models of ALS.
Results
GLP-1R is present in NSC19 cells and in mouse spinal
cord
NSC19 is an immortal mouse neural cell line that exhibits
specific features of spinal cord motor neurons [26], including the
expression of the cholinergic marker choline acetyl transferase
(ChAT), thereby providing a relevant cell culture model for the
study of motor neuron biology and disorders such as ALS. In order
to study mutant SOD1-mediated familial ALS, we established
three stable NSC19 cell lines that expressed vector (as a control),
wild-type (WT) SOD1 or mutated SOD1 (G37R), respectively.
Prior to examining GLP-1R signaling in these cells, GLP-1R
expression was first characterized. As illustrated in Figure 1A,
GLP-1R mRNA is clearly present in all three NSC19 cell lines, as
assessed by RT-PCR with specific mouse GLP-1R primers. In
addition, to both aid translation to animal studies and validate the
value NSC19 cells as an appropriate model of mouse motor
neurons, total RNA was isolated from the spinal cord of wild-type
C57Bl/6 mice and examined for the presence of GLP-1R mRNA
by RT-PCR. Figure 1B demonstrates the presence of the GLP-1R
in mouse spinal cord.
GLP-1R stimulation is neurotrophic and neuroprotective
against oxidative stress and apoptosis in NSC19 cells
To elucidate the effect of GLP-1R stimulation on cell viability
and neuroprotection against oxidative stress in NSC19 cells, cells
were pretreated with 100 nM Ex-4 for 4 h, and H2O2 was then
added to a final concentration of 1.5 mM (established from a dose-
response curve, not shown) to induce oxidative stress and cell
death. Cell viability was thereafter assessed by MTS and LDH
assays at 24 h or 48 h after H2O2 treatment, respectively. As
evident in Figure 2A, 100 nM Ex-4-treatment alone significantly
increased cell viability (to 120% of controls as measured in MTS
assay at 24 h). In accord, cell membrane permeability integrity, as
assessed by LDH release, was significantly improved by Ex-4
treatment alone at 48 h, as compared to controls (Figure 2B).
These data signify that GLP-1R pathway activation by Ex-4 has
neurotrophic actions in NSC19 cells. Treatment of NSC19 cells
with 1.5 mM H2O2 caused a significant decline in cell viability (a
20% decrease in MTS) and a more than 3-fold loss in membrane
permeability integrity (assessed by LDH assay), which were both
significantly ameliorated by Ex-4 pretreatment (Figure 2A and
2B), resulting in a restoration in MTS to a level similar to controls
and a significant amelioration of the H2O2-induced LDH
elevation. These data suggest that Ex-4-induced stimulation of
the GLP-1R pathway provides protection against H2O2–induced
oxidative stress in NSC19 cells. This was assessed further with
staurosporine, which induces apoptosis by activating caspase-3, to
define whether Ex-4 could similarly ameliorate this action. NSC19
cells were pretreated with 100 nM Ex-4 for 24 h before
staurosporine was added at a final concentration of 100 nM. Six
hours after initiation of staurosporine treatment, caspase-3 activity
was quantified in cell lysates. Caspase-3 activity increased 2.5-fold
in staurosporine-treated cells, versus controls, and this increase was
significantly attenuated by Ex-4 pretreatment (Figure 2C). These
data suggest that Ex-4 has an anti-apoptotic action in NSC19 cells,
involving inhibition of caspase-3.
As NSC19 cells express ChAT activity [26], we thereafter
assessed whether the GLP-1R pathway could modulate ChAT
Figure 1. GLP-1R is expressed in NSC19 cells and mouse spinal
cord. (A) A representative RT-PCR analysis showing expression of GLP-
1R in stable transfected NSC19 cell lines (from left to right: NSC19 cells
expressing wildtype SOD1, NSC19 cells expressing empty vector, NSC19
cells expressing G37R mutated SOD1). (B) A representative RT-PCR
analysis showing expression of GLP-1R in wildtype C57Bl/6 mouse
spinal cord (2 lanes represent 2 different mice). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was utilized as an internal control.
Using specific primers, amplified mouse GLP-1R fragment is 250 bp and
GAPDH is 452 bp.
doi:10.1371/journal.pone.0032008.g001
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100 nM or 1 mM Ex-4 or 10 mM of forskolin for 48 h or 72 h.
ChAT activity was then measured in cell lysates using a
radioisotope-based protocol for cultured cells [27]. Ex-4 treatment
significantly elevated ChAT activities at both 48 h (not shown) and
72 h (Figure 2D). Forskolin, a positive control that activates
adenylyl cyclase and thereby increases intracellular levels of cyclic
AMP, also elevated ChAT activity at both times. These data
suggest that activation of the GLP-1R pathway may functionally
improve cholinergic neurons by promoting acetylcholine produc-
tion through elevated ChAT activity, which may provide
beneficial effects for neurodegenerative diseases such as ALS that
involve cholinergic neuron decline.
Protective actions of Ex-4 in NSC19 cells expressing
mutant SOD1
Having established stable NSC19 cell lines that expressed either
wild-type (WT) or mutant (G37R) SOD1, we determined that
5m MH 2O2 treatment for 24 h (established from a dose-response
curve, not shown) induced a more significant death of NSC19 cells
expressing G37R SOD1 than WT SOD1. As shown in Figure 3A,
survival was 5% and 22% in the former and latter, respectively.
Likewise, a 48 h serum deprivation induced a significant loss of
cell membrane permeability integrity in G37R SOD1 NSC19 cells
but not WT SOD1 NSC19 cells, as indicated by elevated LDH
levels in the culture media (Figure 4B). These results signify that
mutant SOD1 NSC19 cells are more vulnerable to stress, such as
induced by oxidative stress and trophic factor withdrawal.
Furthermore, Ex-4 not only lowered basal LDH levels in both
WT and G37R SOD1-expressing cell lines, as previously seen in
control NSC19 cells, but also abolished the serum deprivation-
induced elevation of LDH levels in mutant SOD1 NSC19 cells
(Figure 3B). Together, these cell culture studies suggest that GLP-
1R activation may provide protective effects and ameliorate motor
neuron damage in mutant SOD1 animal models of ALS.
SOD1 (G93A) mouse studies
To define whether the neuroprotective actions of Ex-4 evident
in NSC19 cells translate to in vivo, we studied the SOD1 (G93A)
mouse, a well characterized and widely used animal model of
SOD1 mutation-mediated familial ALS [4,5]. The relationship
between mutant SOD1 mouse models, including their advantag-
es/disadvantages, and human ALS has been reviewed [28,29].
Treatment initiation of SOD1 (G93A) mice began at the age of 6
weeks with either vehicle or Ex-4 via subcutaneous (s.c.) osmotic
pump to provide steady-state delivery. Pumps were replaced every
three weeks to extend treatment over 12 weeks (Figure 4A) until
the occurrence of end stage disease of animals at approximately 18
weeks of age. Consequent to the frailty of the animals, all were
euthanized at 18 weeks age. Preliminary studies indicated that Ex-
Figure 2. GLP-1R stimulation is neurotrophic and neuroprotective against oxidative stress and apoptosis in NSC19 cells. (A–B) Ex-4
is neurotrophic in NSC19 cells and pretreatment with Ex-4 protects cells from H2O2-induced cell death. Cells were pretreated with 100 nM Ex-4 for
4 h, and then exposed to 1.5 mM H2O2. Cell viability was assessed by MTS (A) after 24 h or LDH (B) after 48 h (C: vehicle-treated control; Ex-4:
exendin-4 with and without H2O2,n $6, * p,0.05). (C) Ex-4 pretreatment inhibits apoptosis in NSC19 cells. Exposure to 100 nM staurosporine
significantly induced caspase-3 activity in NSC19 cells, pretreatment with 100 nM Ex-4 for 24 h reduced elevated caspase-3 activity in these cells (C:
vehicle-treated control; Ex-4: exendin-4 with and without staurosporine, n=3, * p,0.05). (D) Ex-4 elevates choline acetyltransferase (ChAT) activity in
NSC 19 cells. NSC19 cells plated on 24-well plates were treated with 100 nM or 1 mM of Ex-4 as well as 10 mM forskolin for 72 h. ChAT activity was
measured in cell lysates and normalized by protein content (n=3, * p,0.05).
doi:10.1371/journal.pone.0032008.g002
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period. In addition, a parallel group of age-matched control WT
(B6SJL-Tg(SOD1)2Gur/J) non-ALS mice were studied, bearing
the same genetic background to SOD1 (G93A) mice.
Glucoregulatory effect of Ex-4 in SOD1 mice
To characterize Ex-4 actions on body weight and glucose
regulation, blood glucose levels and body weight were measured
weekly. Additionally, an intraperitoneal glucose tolerance test
(IPGTT) was performed on day 31 of treatment on fasted animals.
As illustrated in Figure 4B and inset, baseline values of body
weight and blood glucose levels, assessed before initiation of
treatment, were not different between vehicle (saline) and Ex-4
SOD1 (G93A) groups. However, mice receiving Ex-4 underwent
an initial transient drop in body weight when assessed 2 days after
treatment initiation, in line with the known transient action of Ex-
4 on food consumption in rodents [30]. This difference was no
longer evident one week into treatment and, thereafter, no
significant weight differences were evident between the two groups
to end stage disease. Morning non-fasting blood glucose levels
were initially similar (133 and 138 mg/dL) in both groups of ALS
mice, but became transiently elevated in vehicle-treated animals
(155–163 mg/dL), likely consequent to stress hyperglycemia
associated with osmotic pump implantation. By contrast and as
expected, blood glucose levels were unaffected in Ex-4 treated
ALS mice, remaining at a baseline of 135 mg/dL, throughout
most of the study (Figure 4C). However, during advanced disease a
difference in non-fasting blood glucose levels between the vehicle
and Ex-4 treated ALS mice again became evident (Figure 4C). To
define whether Ex-4 treatment altered glucose tolerance in SOD1
(G93A) mice, an IPGTT was performed midway between pump
changes (day 31) in fasted animals at a time that when Ex-4 would
be predicted to be at a steady-state concentration. Figure 4D
demonstrates that not only did Ex-4 vs. vehicle treated ALS mice
have a lower resting blood glucose level (zero time), but Ex-4-
induced a significant decrease in glucose excursion after an i.p.
glucose challenge, providing significantly lowered blood glucose
levels at all times measured throughout the 2 h glucose challenge.
By contrast, and not shown, age-matched control WT non-ALS
mice were normoglycemic.
Ex-4 treatment normalized running behavior in SOD1
mice
Our previous study determined that when running wheels are
provided in each mouse’s cage, presymptomatic SOD1 (G93A)
mice are more active runners (15–20 km/day) than age-matched
control WT non-ALS (B6SJL-Tg(SOD1)2Gur/J) mice (7–9 km/
day) [31]. The SOD1 (G93A) mice then exhibit a sharp decline in
daily running distance 10–20 days prior to the onset of clinical
disease. In the present study, we compared the running behavior
of the two groups of SOD1 (G93A) mice treated with either vehicle
or Ex-4 to assess whether GLP-1R activation modifies this
behavior. Running distances were recorded twice weekly, from
9-weeks of age to end stage disease. As shown in Figure 5A, Ex-4
treated SOD1 (G93A) mice ran significantly less distance daily
(3.2–14.0 km/day) than those treated with vehicle (7.8–21.0 km/
day) throughout their presymptomatic disease stage. The vehicle
SOD1 (G93A) mice thereby ran 4.1–10 km further daily than
their Ex-4 treated littermates, with the latter expressing a running
behavior in line with that previously described for control WT
mice without ALS. However, the change in running behavior did
not impact disease onset, as mean clinical symptom onset dates
were 104 days in vehicle SOD1 (G93A) mice and 102 days in Ex-4
treated mice. Using a 5 point neurological score system (see
Methodology) to track disease onset and progression, we found no
difference between vehicle treated and Ex-4 treated SOD1 (G93A)
mice (Figure 5B), and survival time to decline in neurological
status to stage 4 was similarly no different (Figure 5C).
Ex-4 treatment preserved lumbar spinal cord structure,
neuron density and specific markers in SOD1 (G93A)
mice
SOD1 (G93A) mice were euthanized at both 15-weeks (early
symptomatic disease stage, n=5 per group) and 18 weeks of age
(end stage, n=10 per group), and age-matched control WT non-
ALS mice (n=4) were likewise euthanized for analysis of spinal
cord. Representative micrographs of cresyl violet-stained lumbar
spinal cord are shown in Figure 6A, highlighting the Nissl
substance in the neurons. Readily apparent are structural
alterations in spinal cord morphology from SOD1 (G93A) vehicle
treated animals, particularly in relation to the boundary between
Figure 3. Ex-4 is neuroprotective in NSC19 cells expressing either WT SOD1 or G37R SOD1. (A) G37R SOD1 NSC19 cells are more
vulnerable to oxidative stress (H2O2 (5 mM) for 24 h) than are WT SOD1 NSC19 cells. Cell viability assessed by MTS assay shows 22% cell survival in WT
SOD1 cells v.s. 5% survival in G37R SOD1 cells (n=6, * p,0.05). (B) Ex-4 reduced cell membrane permeability and protected cells from serum
deprivation in both WT SOD1- and G37R SOD1-expressing NSC19 cells. Cells were cultured in no-serum media for 48 h in the presence and absence
of 100 nM Ex-4. Cell viability was assessed by LDH assay. LDH levels were significantly reduced by Ex-4 treatment in both cells, under conditions of
either Ex-4 alone or Ex-4 plus no-serum stress (C: vehicle-treated control; Ex-4: exendin-4; no serum: serum deprivation, n=5, * p,0.05).
doi:10.1371/journal.pone.0032008.g003
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e32008Figure 4. Design of animal study and gluco-regulatory effects of Ex-4 in SOD1 (G93A) mice. (A) Scheme of animal study: SOD1 (G93A)
mice were assigned to two groups (n=15 mice/group), starting at the age of 6 weeks, saline or Ex-4 was delivered via subcutaneously implanted
osmotic pumps in the control group and Ex-4 treatment group, respectively, throughout the study (treatment duration 12 weeks, hence mice were
Exendin-4 in Amyotrophic Lateral Sclerosis Models
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32008white and grey matter regions (Figure 6B), as compared to control
wild-type mice (Figure 6C). In particular, the demarcation of the
ventral and dorsal grey matter horns is unclear, and suggestive of
motor neuron dysfunction or loss within these areas. In contrast, in
Ex-4 treated SOD1 (G93A) mice spinal cord, the morphology of
the lumbar structure appeared more typical, with both ventral and
dorsal horns clearly visible, suggesting preservation of spinal cord
structure and neurons (Figure 6A). To more clearly characterize
changes, quantification of presumptive motor neuron cell bodies
within the ventral horn was undertaken (Figure 6B) to determine
neuron density. Figure 6D illustrates the presence of 3-fold more
neurons within the spinal cord section of Ex-4 treated SOD1
(G93A) mice compared to vehicle SOD-1 (G93A) mice at both
early and end stage disease. This result suggests that Ex-4
18-weeks old at endstage) and pumps were changed every 3 weeks. (B) Baseline and weekly body weight of control (saline) and Ex-4-treated SOD1
(G93A) mice were largely similar throughout the study. Both mean baseline and weekly body weights were not different between the two groups of
SOD1 (G93A) mice, except at the first measurement on day 2 post-treatment, when the body weight of Ex-4 treated mice transiently dropped
compared to controls. The mean body weight of the Ex-4 group thereafter quickly caught up and remained comparable to controls throughout the
study (n=10–15, * p,0.05). (C) Baseline and weekly blood glucose levels of saline or Ex-4-treated SOD1 (G93A) mice. Morning fed blood glucose
levels were measured weekly from tail tips. In general, blood glucose levels in Ex-4 treated mice were regulated between 120–140 mg/dL, whereas
those for controls varied between 125–160 mg/dL. Mean blood glucose levels were largely comparable between the two groups, except during the
first 2 weeks and last week of the study, when levels were significantly higher in the control group (n=10–15, * p,0.05). (D) Intraperitoneal glucose
tolerance test (IPGTT) at day 31 of treatment in SOD1 (G93A) mice. Assessment of mean blood glucose levels during a 2-hour IPGTT demonstrated
significantly lower levels in Ex-4-treated mice at all time points (0, 10, 20, 30, 60, 90, 120 min) measured during IPGTT (n=7, * p,0.05).
doi:10.1371/journal.pone.0032008.g004
Figure 5. Behavioral effects of exendin-4 action in SOD1 (G93A) mice. (A) Comparison of average daily running distances of vehicle-treated
and Ex-4-treated SOD1 (G93A) mice. During a presymptomatic stage (approximately 62–95 days of age), Ex-4 treatment significantly reduced average
daily running distance of SOD1 (G93A) mice, resulting in 3.2–14.0 km/day (Ex-4 group) v.s. 7.8–21.0 km/day (vehicle group) (n=10–15, * p,0.05,
** p,0.01, *** p,0.001). This Ex-4 induced decline brought the running in line with our prior studies of SOD1 WT non-ALS (B6SJL-Tg(SOD1)2Gur/J)
mice [31]. At the age of 95 to 105 days, running activities quickly declined in both SOD1 (G93A) groups in a similar pattern, resulting in disease onset
at the same time. (B) Neurological scores of SOD1 (G93A) mice. The neurological score between day 93–125 shows no difference between vehicle-
treated and Ex-4-treated SOD1 (G93A) mice. (C) Kaplan-Meier plots of the survival of vehicle- and Ex-4 treated SOD1 (G93A) mice to reach a
neurological score of 4 (paralysis of hind limbs [29]). No difference was evident between the two groups (n=10 per group, log-rank statistical
analysis, p=0.8).
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tion in ALS mice, particularly since neuron density was reduced
but not substantially different from that in control non-ALS mice.
To define whether Ex-4 treatment for 9 and 12 weeks improved
function of motor neurons at the cellular level, immunohisto-
chemical staining of spinal cord sections was performed utilizing
antibodies against specific markers (Figure 7). Neurodegenerative
conditions such as ALS are associated with an up-regulation of
glial fribrillary acidic protein (GFAP), a glial cell marker [4,5]. As
shown in Figure 7A, GFAP immunostaining intensity is signifi-
cantly less in Ex-4 treated SOD1 (G93A) mouse spinal cord than
in vehicle treated animals, reaching a difference of approximately
4-fold (Figure 7C). Caspase-3 is an apoptotic marker, and caspase-
mediated programmed cell death has been reported as an
important mechanism for motor neuron loss in SOD1 (G93A)
mice [32]. Utilizing an anti-activated caspase-3 antibody,
Figure 7B demonstrates that caspase-3 immunostaining intensity
is 3-fold less in Ex-4 treated SOD1 (G93A) mouse spinal cord at
early stage (9 weeks Ex-4 treatment) and 4-fold less at end stage
disease, as compared to vehicle treatment. These caspase-3 levels
in Ex-4 treated SOD1 (G93A) mice approached levels present in
control non-ALS WT mice, suggesting that Ex-4 inhibited
caspase-3-mediated apoptosis in SOD1 (G93A) mice, and
providing a potential mechanism to account for the described
motor neuron protection. Choline acetyl transferase (ChAT) is a
marker of cholinergic neurons, the primary component of motor
neurons. As illustrated in Figure 7D, a substantial decline in ChAT
immunointensity was evident within the spinal cord of SOD1
(G93A) vehicle treated mice that was not found following Ex-4
treatment. Five-fold higher levels were present in Ex-4 versus
vehicle treated SOD1 (G93A) mice, approaching those found in
control non-ALS WT mice (Figure 7F), and supporting an Ex-4
mediated preservation of cholinergic neurons in the spinal cord of
treated mice. Finally, SMI-32 is a neurofilament marker to define
neuronal cells, interacting with a nonphosphorylated epitope in
neurofilament H of most mammalian species. As found for ChAT,
a clear decline in SMI-32 immunostaining was evident in the
spinal cord of SOD1 (G93A) vehicle, but not Ex-4 treated mice.
Levels in the latter approached those present in control non-ALS
WT mice and, likewise, suggest a preservation of spinal cord
neurons in SOD1 (G93A) mice following Ex-4 treatment
(Figure 7E & F).
Discussion
This study demonstrates that the GLP-1R agonist Ex-4, a well-
tolerated drug approved for the treatment for T2DM [7,8], has a
range of beneficial neuroprotective as well as neurotrophic
Figure 6. Ex-4 treatment preserved lumbar spinal cord structure and neuron density. (A) Cresyl violet staining of lumbar spinal cord
section of SOD1 (G93A) mice at both early (9 weeks of treatment at a pre-symptomatic stage) and end stages of disease. (B) Close-up of ventral horn
of grey matter shows staining of motor neurons with large soma, scale bars on right inset is 25 mm. By comparison, (C) demonstrates similar lumbar
spinal cord sections derived from control non-ALS WT mice, in which the grey matter tracts are clearly evident. (D) Quantification of motor neuron
numbers in the ventral horn of grey matter. An approximately 3-fold greater neuron number was present in SOD1 (G93A) Ex-4-treated mice spinal
cord sections than in vehicle-treated mice at both pre-symptomatic and end disease stages (9 and 12 week treatment times). Evaluation of motor
neuron number in the lumbar ventral horn grey matter of age-matched control non-ALS WT mice were in the range of those present in SOD1 (G93A)
mice treated with Ex-4. Selection of large pyramidal neurons was based on their characteristic nulceolus, angular and spindle-shaped [85]. A
measuring bar of 25 mm is for reference only.
doi:10.1371/journal.pone.0032008.g006
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e32008Figure 7. Ex-4 treatment modified cell type specific markers of spinal cord in SOD1 (G93A) mice towards levels present in control
non-ALS WT mice. (A & C) Glial fibrillary acidic protein (GFAP) is a glial cell marker and is usually up regulated under neurodegenerative conditions
[86]. Ex-4 treatment significantly reduced GFAP immunostaining in SOD1 (G93A) mice spinal cord. (B & C) Caspase-3 is an apoptotic marker. There are
3- to 4-fold less numerous activated caspase-3 neurons in Ex-4-treated G93A SOD1 mice lumbar spinal cord sections. (D & F) Choline acetyl
transferase (ChAT) is a cholinergic neuron marker. Immunostaining with specific ChAT antibody shows significantly greater ChAT immunointensity in
Ex-4-treated SOD1 (G93A) mice. (E & F) SMI-32 is a neurofilament marker that interacts with a nonphosphorylated epitope in neurofilament H of most
mammalian species. There is greater SMI-32 immunointensity in SOD1 (G93A) mice (n=5, ** p,0.01, *** p,0.001). For all investigated markers, Ex-4
treatment of SOD1 (G93A) mice substantially ameliorated the dramatic differences evident between vehicle SOD1 (G93A) and control non-ALS WT
mice (C & F).
doi:10.1371/journal.pone.0032008.g007
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Importantly, some of these actions effectively translated from
normal and SOD1 (G37R) mutation neuronal cultures into a well-
characterized SOD1 (G93A) mouse model of ALS to provide
improved glucose tolerance, a preservation of lumbar spinal cord
structure and neuron density, an amelioration of the loss of specific
spinal cord markers, a concomitant reduction in apoptotic markers
in spinal cord, and a change in wheel running behavior towards
that of the wild-type. Our data hence suggest that stimulation of
the GLP-1R pathway may provide beneficial properties for motor
neurons, and therefore warrants further investigation to define its
therapeutic potential for the treatment of ALS.
GLP-1R expression has been described throughout the brain,
including the hypothalamus, cortex, hippocampus, striatum,
substantia nigra and brain stem, as well as subventricular zone
[9–11]. Under normal physiological conditions, its expression is
primarily confined to large output neurons, epitomized by
pyramidal and dentate granule neurons as well as Purkinje cells,
where, in particular, it localizes to dendrites and on or near
synapses [11]. Recent studies have demonstrated that GLP-1R
agonists enhance synaptic plasticity [33,34], strengthening long-
term potentiation [33] and improving cognitive performance [35],
in accord with GLP-1R over-expression mice exhibiting enhanced
learning [36] and knockouts with impaired memory formation
[37]. The expression of GLP-1R in spinal cord has been previously
shown by in situ hybridization analysis [38], in which scattered
GLP-1R mRNA containing cells, that included motor neurons,
were apparent within the gray matter. Herein, we directly
demonstrate by RT-PCR that GLP-1R mRNA is present within
mouse spinal cord as well as in the motor neuron/neuroblastoma
cell line NSC 19, implicating a potential function of GLP-1 in
motor neurons, and providing support for GLP-1R as a drug
target.
In accord with our prior studies in cellular models of AD, stroke
and PD in which Ex-4 proved to be neuroprotective against, Ab-,
hypoxia- and 6-hydroxydopamine-induced neuronal toxicity,
respectively [15,16], Ex-4 proved to be protective for NSC 19
cells challenged with oxidative stress at a concentration within a
clinically achievable realm [39]. Ex-4, additionally, ameliorated a
classical staurosporine-induced apoptotic insult that is known to
involve caspase-3 activation, and protected not only NSC19 WT
SOD1 but also mutant SOD1 (G37R) expressing cells, which were
more vulnerable to oxidative stress, from cellular dysfunction
consequent to trophic factor withdrawal. Likewise, and in accord
with the Ex-4 induced elevated expression of the dopaminergic
marker, tyrosine hydroxylase, in unchallenged primary dopami-
nergic neurons [15], GLP-1R activation proved to be neurotroph-
ic in unchallenged NSC19 cells, elevating expression of the
cholinergic marker, ChAT, and increasing cell viability. The GLP-
1 signaling pathway is initiated by Ex-4 and GLP-1 binding to its
receptor, a 7-transmembrane protein that belongs to the class B1
G-protein-coupled receptor family [40]. The GLP-1R is associated
with adenylyl cyclase that, upon activation, increases intracellular
cAMP levels. Downstream of cAMP, many GLP-1 actions have
been associated with activation of PKA, PI3K and MAPK [7].
Our prior studies demonstrated that PKA and PI3K mediated
pathways are particularly important in the neurotrophic and
neuroprotective actions of Ex-4 and GLP-1 in neuronal cultures
[15,16], with MAPK playing a supportive role [14]. GLP-1 actions
mediated through MAPK-independent signaling and growth
factor–dependent Ser/Thr kinase AktPKB have additionally been
described [41]. Interestingly, a recent study in a similar motor
neuron cell line, NSC34, describes GLP-1 protection of motor
neurons against glucosamine via an Epac-mediated pathway [42].
Thus, similar to pancreatic cells [43], multiple potentially parallel
pathways are involved in neuronal trophic/protective actions of
GLP-1R activation and it will be interesting to see in future
experiments which downstream pathway(s) are most relevant in
motor neurons.
A recent study using SOD1 (G93A) mice demonstrated that,
compared to WT mice, mutant mice run significantly greater daily
distances on a running wheel [31], in line with a documented
increased excitability of motor neuron axons in ALS patients [44].
Although disease onset and progression was not correlated with
the cumulative running distance of SOD1 (G93A) mice, a clear
decline in running distance was readily observed at age 15 weeks
that preceded the classical ALS symptomatic stage by 7 to 10 days.
In the present study, this likewise proved to be the case, thereby
confirming our previous finding. Interestingly, we determined that
Ex-4 treatment significantly lowered daily running activity of
SOD1 (G93A) mice compared with those administered vehicle, to
provide a running behavior in line with WT mice. Albeit the
mechanism(s) underlying the increased running phenomenon in
SOD (G93A) mice remain unknown [31], the change in behavior
provided a valuable pre-symptomatic point to characterize motor
neurons at the level of the lumbar spinal cord, and additionally
assess the in vivo translation of beneficial cellular actions of Ex-4.
Both GLP-1 and Ex-4 appear to readily cross the blood-brain
barrier and enter brain following their systemic administration
[12,13]. In accord with previous reports of beneficial cellular
neuroprotective actions of GLP-1R activation translating to
improvements in animal models of stroke [15,18], PD [15,19–
21], AD [17,23,45,46] and Huntington’s disease [47], a clear
amelioration of neuronal loss was evident by immunohistochem-
ical analyses within the ventral horns of the lumbar spinal cord of
Ex-4 treated SOD1 (G93A) mice. Specifically, the substantial
approximately 80% loss of motor neurons evident both pre-
symptomatically and at end stage disease was reduced to a ,20%
loss following Ex-4 treatment, with similar degrees of preservation
assessed by quantifying the intensity of both ChAT and the
neuronal cell neurofilament protein, SMI-32.
In both human ALS [48] as well as in SOD1 (G93A) mice,
reactive astrocytosis is a hallmark of the disease, particularly
during the symptomatic phase when hind limb weakness becomes
increasingly evident [49]. Our studies indicate the occurrence of
astrocytosis, evident from a dramatic elevation of GFAP in the
ventral horn of lumbar spinal cord, at both presymptomatic and
end stage disease that was largely ameliorated by Ex-4.
Accumulating evidence supports a role for astrocytes in disease
propagation and advancement of motor neuron dysfunction and
subsequent apoptosis mediated by a combination of cell-
autonomous and non–cell-autonomous processes [50–52]. Astro-
cytes are clearly critical partners of motor neurons, providing them
both trophic support and, via the action of their glial glutamate
transporter (EAAT2), rapidly recovering and thereby lowering
synaptic glutamate following neuronal excitation. Under condi-
tions where SOD1 (G93A) motor neurons are more vulnerable to
physiological stress [51] and SOD1 (G93A) glial cells are less able
to support motor neuron survival [51,52], a depleted expression of
EAAT2, resulting in elevated glutamate and potential of
excitotoxicity, together with glial cell activation and concomitant
release of proinflammatory cytokines, described in cellular and
animal models of ALS [53], clearly has greater likelihood to impair
the function of neighboring motor neurons and induce apoptosis.
Likewise, interactions involving microglia-motor neuron signal-
ing are implicit in motor neuron health and survival [54], and
GLP-1R expression has been described on microglia [55].
Microglia mediate a balance between neuroprotection and
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support, activated (M1) microglia produce and release nitric oxide,
superoxide radicals and peroxynitrite that mediate oxidative
damage, together with proinflammatory cytokines that can lead
to motor neuron injury and death [54]. Activated M1 microglia
are an early pathological hallmark of human ALS [56] and occur
at a preclinical disease stage in the spinal cord of ALS (G93A) mice
[57]. Numerous studies suggest that activated mutated SOD1
microglia more readily switch from survival-promoting to death-
promoting with accompanying enhanced release of neurotoxic
factors [58], and that excessive oxidation of wild type SOD1 can
result in misfolded protein that may acquire the binding and toxic
properties characteristic of mutated SOD1 [59], conceptually
linking pathways as potentially common between familial and
sporadic ALS [60,54]. Not only does GLP-1R activation provide
neurotrophic support and mitigate oxidative stress-induced
cellular damage [Figure 2 & 3], but it has been reported to
suppress the activation of microglia and inhibit their production of
proinflammatory cytokines [55].
The beneficial actions of Ex-4 in SOD1 (G93A) mice are thus
potentially mediated at a number of levels, and certainly at the level
of improving glucose regulation (Figure 4D) that, similar to human
ALS [61], appeared impaired, particularly during advanced disease
[62]. Glucose intolerance and insulin dysregulation are evident
across a number of neurodegenerative diseases, may contribute to
disease progression and are clearly worth ameliorating [63]. As the
GLP-1R has as been reported on skeletal muscle [64] as well as on
peripheral neurons [65], where its activation is neuroprotective
[22,66], Ex-4 may provide additional peripheral actions in ALS
mice at these levels. Moreover, GLP-1R expression has been
reported present on glial cellsduringinjury [67], andadministration
of Ex-4 in models of PD [20,21] and stroke [18] has been shown to
reduce both glial cell activation and levels of proinflammatory
cytokines, thereby diminishing neuroinflammation. In addition to
the described neuroprotective actions under conditions of oxidative
stress, Ex-4 has likewise been shown to be protective against
glutamate toxicity [45], and to reduce caspases-3 activation and
lower Bax expression [15,16] via which SOD1 (G93A) motor
neuron death has been reported to occur [51,53]. GLP-1R
expression has been demonstrated within the subventricular zone
and systemic Ex-4 administration has been reported to stimulate
andeffectivelysupportneurogenesis[19],whichappearsdeficientin
adult ALS models [53,68]. Furthermore, GLP-1R activation
provides neurotrophic actions and not only elevates expression of
cholinergic markers and protects neurons from trophic factor
withdrawal, but has additionally been reported to promote vascular
endothelial growth factor (VEGF) production [69], a trophic
protein whose levels are diminished in the plasma and CSF of
ALS patients [70] and whose elevated expression appears to
improve the survival of SOD1 (G93A) mice [71,72].
Although Ex-4 clearly demonstrated neuroprotective/neuro-
trophic motor neuron actions in cellular and animal models of
ALS, our in vivo study did not show evidence of symptom free
improvement or altered disease progression following Ex-4
treatment (Figures 5B,C), albeit our study was not specifically
designed to assess survival. Nevertheless, Ex-4 substantially
impacted a number of measures that may translate to quality of
life improvements. We cautiously interpret the lack of impact on
disease progression by proposing two scenarios, which are not
mutually exclusive. First, it is possible that our observed Ex-4-
induced preservation of motor neurons may not have been
sufficiently physiologically functional to offset neurological deficits,
which occur with a particularly steep progression in SOD1 (G93A)
mice. The Ex-4 concentrations utilized in our studies are in the
realm of those present in human following routine 10 ug
subcutaneous Ex-4 administration that achieves plasma levels of
200 pg/ml (48 nM) [39], but higher human doses have been safely
administered and could hence be utilized in future preclinical ALS
in vivo studies. Second, although alterations in distal motor axons
are amongst the earliest pathological changes in the pathogenesis
of ALS, followed by a ‘‘dying back’’ process [73,54], some studies
[74] have questioned the origin of ALS and proposed that
molecular events occurring within muscle fibers – including
oxidative stress, mitochondrial dysfunction and hypermetabolism
– may detrimentally impact neuromuscular junction innervation
and, thereby, induce motor neuron failure. In this regard, Rouaux
and colleagues [75] reported the neuroprotective actions of
sodium valproate in ALS mice, mediated via CREB-binding
protein dependent mechanisms, which GLP-1 and agonists also
have been reported to influence when inducing pancreatic beta
cell survival [76,77]. Sodium valproate, like Ex-4, did not however
appear to extend the mean survival of ALS mice [75], potentially
because it did not ameliorate skeletal muscle denervation. Whereas
the GLP-1R, although potentially different from that present on
beta cells [78], appears present and functional in skeletal muscle
[64], its existence has yet to be evaluated at the neuromuscular
junction. Nevertheless, these results should be viewed in the light
of Riluzole, the only approved drug for ALS, that provides a life
extension in SOD1 (G93A) of only 10% [79,80]. Hence future
studies of Ex-4 in ALS may warrant assessment of end plate
denervation/neuromuscular integrity, nerve conduction time and
possibly sciatic nerve diameter to aid characterize physiological
function at this peripheral level. In addition, further analysis of Ex-
4 following earlier treatment initiation together with a higher Ex-4
dose in SOD1 (G93A) is merited. As may be studies of Ex-4 in the
TDP-43 ALS mouse model [81–83], which has a slower
progression following the occurrence of neurological deficits to
potentially allow the assessment of therapy after disease onset.
Such studies may further optimize the impact of Ex-4 to allow a
clearer determination of clinical translation potential in a disease
for which current treatment is clearly unsatisfactory.
Materials and Methods
Materials
Peptides (GLP-1 and Ex-4) were obtained from AnaSpec
(Fremont, CA). Hydrogen peroxide, staurosporine, forskolin and
other reagents were from Sigma (St. Louis, MO). Cell culture
media and other cell culture supplements were from Invitrogen
(Carlsbad, CA), with the exception of Fetal clone 3 (FC3) serum
that was from HyClone (Logan, UT). M-PER cell lysis buffer was
from Thermo Fisher Scientific (Rockford, IL).
Cell cultures
Original NSC-19 cell line was generated by somatic cell fusion
of mouse neuroblastoma N18TG2 cells with motor-enriched
spinal cord cultures from embryonic day 12–14 mice [26]. Stable
NSC-19 cell lines that express wild-type SOD1, mutated SOD1
(G37R) or vector control are established in our laboratory [84].
These NSC-19 cell lines were maintained at 37uC in a 5% CO2
atmosphere in Dulbecco’s modified Eagle’s medium supplemented
with 10% FC3 serum, 100 U/mL penicillin/streptomycin and
0.2 mg/ml G418. Cells were split, 1:3 ratio, every 3–5 days.
RT-PCR
Total RNA was extracted from NSC-19 cells cultured on
100 mm dishes by utilizing GenElute
TM Mammalian Total RNA
Miniprep Kit from Sigma. RNA quality and quantity were
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One microgram total RNA was used for RT-PCR to identify the
presence of the GLP-1R. SuperScript III First-strand Synthesis
Supermix (Invitrogen) was utilized for the reverse transcription
step, followed by regular PCR. Primers used for PCR were: GLP-
1R, forward: 59 AGGAACCCTACGCTTCGTCAAG 39 and
reverse: 59 TTTGGCAGGTGGCTGCATACAC 39, expected
PCR product is 250 bp; GAPDH, forward: 59 TCCACCAC-
CCTGTTGCTGTAG 39 and reverse: 59 GACCACAGTCCAT-
GACATCACT 39, expected PCR product is 452 bp.
LDH and MTS assays
Cell viability was assessed by LDH (LDH assay kit, Sigma) and
MTS assays (CellTiter 96 Aqueous One Solution Cell Prolifera-
tion Assay kit, Promega, Madison, WI), as described previously
[16].
Caspase-3 activity
Cellular levels of caspase-3 activity were quantified using a
colorimetric caspase-3 assay kit (Sigma) in a 96 well plate
microassay, as per the manufacturer’s protocol and described
previously [16].
ChAT activity
ChAT activity was quantified utilizing a technique specifically
optimized for cell culture studies [27].
Animal studies
Thirty male B6SJL-Tg(SOD1*G93A)1Gur/J (stock # 002726)
mice and four age-matched wild-type control (B6SJL-Tg(SOD1)2-
Gur/J) mice were purchased from Jackson Laboratories (Bar
Harbor, ME) and were housed under controlled 12 hr light/12 hr
dark cycle and temperature conditions, with food and water
available ad libitum. Animal studies were undertaken on an
approved protocol (290-LNS 2013) of the National Institute on
Aging Intramural Research Program, and were carried out in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of Health.
At the start of the study, mice were individually housed and
randomly assigned into two groups: group 1: 15 SOD1 (G93A)
vehicle mice received saline; group 2: 15 SOD1 (G93A) treatment
mice received Ex-4. Starting at the age of six weeks, either saline or
Ex-4 were administered to mice via s.c. implanted ALZET Micro-
osmotic pumps (Model 1004, Alzet, Cupertino, CA). Ex-4 was
dissolved in saline and delivered at a rate of 3.5 pmoles/kg/min.
Pumps were changed every 3 weeks for additional 3 times to
maintain a steady-state concentration of Ex-4. This thereby
provided a total treatment duration of 12 weeks. In all animals,
pumps wereplacedsubcutaneously, posterior to the scapulae.Pump
implantation and replacement were performed under anesthesia
(isoflurane, Abbott Laboratories, Chicago, IL) utilizing sterile
procedures. Body weight and blood glucose levels (determined
from tail blood by glucometer) were monitored every week. Five
mice in both SOD1 (G93A) groups were euthanized at the time of
the final (3
rd) pump replacement when mice were 15-weeks of age
and had undergone a total of 9 weeks of treatment. The remaining
mice (n=10) in each group were maintained to end stage disease
(definedbyaneurologicalscoreof4)andweretheneuthanized.The
wild-type control mice were not treated with Ex-4.
Intraperitoneal glucose tolerance test (IPGTT)
An IPGTT was performed on day 31 of treatment (approxi-
mately midway between pump replacements). Mice were fasted
overnight before the glucose tolerance test. Glucose (1.5 g/kg
body weight) was administered by i.p. administration. Blood
glucose levels were measured by glucometer from samples
obtained from the tail vein immediately prior to glucose injection
(0 time) and at 10, 20, 30, 60, 90, and 120 min thereafter.
Behavioral measurement
Mice were individually caged at the start of the study. Two
weeks after the initiation of treatment, at 8 weeks of age, mice were
transferred to individual cages containing an exercise wheel (Super
Pet, IL) coupled to a bicycle computer (Sigma Sport USA, IL).
Maximum speed, average speed and total running distance were
recorded twice per week, one week later at 9 weeks of age. The
motor function of all mice was also scored twice per week using a
5 point clinical observation of the hind limbs with the following
stages: 0, normal gait (100%); 1, single leg limp (75%); 2, single leg
paralysis (50%); 3, second leg limp (25%); 4, second leg paralysis
(0%) [31]. Mice were euthanized on reaching stage 4. Disease
onset was defined when the neurological score=1, whereas disease
progression was the rate (days) that it took a mouse to go from a
neurological score of 1 to 4. Statistical analyses were performed
using Statview software.
Cresyl violet staining of spinal cord and motor neuron
counts
Mice were anesthetized deeply and perfused transcardially with
20 ml filtered cold PBS followed by 20 ml 4% paraformaldehyde.
Spinal cords were removed, placed into 4% paraformaldehyde,
and kept at 4uC overnight. Cords were then stored for
cryoprotection in 30% sucrose overnight. The lumbar spinal cord
was removed from the remainder of the spinal cord and cut into 4-
mm-long segments. Segments were embedded in OTC freezing
medium and sectioned axially at 7 um at 225uC with a Microm
Cryostat II, equipped with the Cryo-Jane System (Instrumedics
Inc.) for preservation of tissue structure. Every fifth section was
stained with 0.1% (w/v) cresyl violet acetate (Nissl stain) without
counterstain. Motor neurons in the ventral horn were quantified
by counting large pyramidal neurons that stained with cresyl violet
and possessed a prominent nucleolus. A minimum of 11 sections of
spinal cord were counted per mouse, and all analyses were
performed blindly. A minimum of 5 animals per SOD1 (G93A)
group were analyzed, and 4 age-matched control wild-type mice
were additionally assessed.
Immunohistochemistry
Mouse spinal cords were fixed, as described above, for the cresyl
violet–stained sections. Tissues were exposed for 60 min to PBS
containing 0.1% Triton X-100 (Research Organics Inc, Cleve-
land, OH) and 10% normal goat serum (Sigma, St. Louis, MO) to
block nonspecific antibody binding, followed by incubation
overnight with primary antibody for the following sets of primary
antibodies: (a) Monoclonal Anti-Glial Fibrillary Acidic Protein
(1:200; Sigma, Saint Louis, MO), (b) anti-activated caspase-3 pAb
(1:250, Promega, Madison WI) and (c) ChAT Rabbit pAb (1:200,
Abcam, Cambridge, MA) overnight at 4uC. To test for nonspecific
staining by the secondary antibodies, additional slides were
processed in a similar fashion with the primary antibodies
excluded. All slides were then rinsed for 1 hr at room temperature
in several changes of PBS and incubated in the dark for 1 hr at RT
in PBS that contained 5% NGS and the fluorescent secondary
antibody, Alexa Fluor 568-conjugated IgG (1:200). Following
incubation with secondary antibody, images were acquired by
Nikon Eclipse E600 fluorescence microscope. These images were
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ments, Sterling Heights, MI and Photoshop 7.0 (Adobe Systems,
San Jose, CA), with the input levels adjusted to span the range of
acquired signal intensities exactly.
Quantification of immunohistochemistry
Using spatially calibrated images with the automated measure-
ment tools in IP lab software (BD Biosciences Bio-imaging,
Rockville, MD) total area of positive pixel intensity was measured
and analyzed with paired t-test using GraphPad Prism version
5.00 for Windows, GraphPad Software, San Diego California
USA.
Statistical analyses
Data are provided as mean values 6 standard error of means.
Paired or, where appropriate, unpaired student’s t-test and one-
way ANOVA were used for statistical evaluation. A Dunnett’s t-
test was utilized for comparison of multiple samples, with
Bonferonni correction as required. The sample number (n)
together with significance (p) and additional statistical analyses
are provided in each Figure legend.
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